Heartflow, Inc. Common Stock (HTFL) - Stock Analysis
Last updated: May 11, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
HeartFlow (HTFL) has multiple fresh growth catalysts—Aetna coverage expansion Jan 6, 2026, new clinical data at ACC and the launch/enrollment of the 5,000‑patient NAVIGATE‑PCI registry on March 16, 2026—and its stock has surged ~20–30% off the March low, positioning it as a high‑beta, event-driven healthcare IT momentum trade despite ongoing operating losses.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • Strong Liquidity • Persistent Losses • Negative FCF HTFL has a strong cash-rich balance sheet and low leverage, but persistent losses, negative free cash flow, and a rich sales multiple make the stock dependent on a turnaround.
Price Behavior
Key Price Behavior Insights: • Higher-low base • Momentum fade • Reclaim $30 Support Level: $28.67 Resistance Level: $29.96-$30.29 HTFL's last month trend remains constructive as it held above its early-April base and rebounded from the high-$28s, but fading momentum and lower highs mean it must reclaim $30–$31.73 to resume the advance.
Sentiment & News
Key News Insights: • Patent defense • Earnings ahead • Mixed sentiment Heartflow faces heightened scrutiny as it sues Cleerly over patent infringement, heads into Q1 earnings on May 14, and remains under mixed analyst and institutional signals.
AI Summary
HTFL is evolving from a speculative AI healthcare name into a clinically validated platform with real IP value, but the investment case now hinges on converting that traction into operating leverage before ongoing cash burn, a 12.4x sales valuation, and the Cleerly patent fight pressure the multiple.
Description
HeartFlow offers a non-invasive diagnostic platform that converts a single coronary CT angiogram into a patient-specific 3D heart model and applies computational fluid dynamics and related analytics to quantify blood flow, arterial narrowing, and plaque characteristics. Founded in 2007 and based in Mountain View, California, the company distributes its technology globally to support clinical assessment and management of coronary artery disease.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Mar 23 | Mar 30 | HTFL | Heartflow, Inc. Common Stock | HeartFlow (HTFL) has multiple fresh growth catalysts—Aetna coverage expansion Jan 6, 2026, new clinical data at ACC and the launch/enrollment of the 5,000‑patient NAVIGATE‑PCI registry on March 16, 2026—and its stock has surged ~20–30% off the March low, positioning it as a high‑beta, event-driven healthcare IT momentum trade despite ongoing operating losses. | Closed | -11.0% |